This breast cancer thought-leader discussion, with associated slide deck and eNewsflash, provides participants with valuable updates and expert perspectives on exciting new data in hormone receptor (HR)-positive breast cancer released at the 2018 European Oncology Congress in Munich.
Oct 25, 2018
Oct 25, 2019
Robert Coleman, MD, FRCP, FRCPE,
Medical Director, prIME Oncology,
University of Sheffield
Weston Park Hospital, Sheffield, United Kingdom
- Richard de Boer, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia
- Hope S. Rugo, MD, FASCO, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Abstract #LBA3_PR: Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the Phase 3 SOLAR-1 trial
Abstract #LBA2: Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3
Abstract #290O: Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3
Abstract #291O: Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
Abstract #293PD_PR: Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial
Abstract #339P: Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: analysis of the MONARCH trials
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Richard de Boer, MBBS, FRACPPeter MacCallum Cancer Centre
Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
This educational activity is specifically designed for oncologists and other healthcare professionals involved in the management of patients with HR-positive breast cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data investigating the safety and efficacy of combination approaches for HR-positive, HER2-negative breast cancer
- Select appropriate treatment approaches for HR-positive, HER2-negative breast cancer and identify the optimal sequence of treatment options
This educational activity is supported by a grant from Novartis Oncology.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr De Boer has disclosed that he has received honoraria for promotional speaker’s bureaus from Amgen, Novartis Oncology, and Roche. He has disclosed membership on advisory committees or review panels for Amgen, Eisai, Novartis Oncology, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rugo has disclosed independent contracting for Daiichi, Eisai, Genentech, Eli Lilly, Macrogenics, Merck, Novartis Oncology, OBI, Odonate, Pfizer, and Plexxikon. She has also received travel support from Amgen, Eli Lilly, Merck, Mylan, Pfizer, and Puma. She has received honoraria from Celtrion. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
- Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships